Some Hematological Profile in Children With Chronic Kidney Disease
NCT ID: NCT06143098
Last Updated: 2024-02-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
102 participants
OBSERVATIONAL
2024-03-01
2025-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
* Complete blood picture
* Coagulation profile (PT, PC, PTT)
* Iron study
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Methylation Biosignature in Childhood Chronic Kidney Disease
NCT02022046
The Influences of Malnutrition and Inflammation Complex Syndrome in Hemodialysis Patients
NCT00190125
Cardiac Biomarkers and Iron Status in Hemodialysis Patients
NCT05256004
Pattern of Menorrhagic Female Attending the Hematology Unit in Assuit University Children Hospital
NCT06660459
Retrospective Analysis of Renal Prognosis in Patients With Chronic Kidney Disease
NCT03201406
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
CKD is defined by the presence of kidney damage or an estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m2, it can last for 3 months or longer, regardless of the cause. Chronic kidney disease (CKD) is recognized as a major non-communicable disease in children. (Inker.,et al2014).
CKD is classifies it into 6 categories based on glomerular filtration rate (G1 to G5 with G3 split into 3a and 3b). It also includes the staging based on three levels of albuminuria (A1, A2, and A3), with each stage of CKD being sub-categorized according to the urinary albumin-creatinine ratio in (mg/gm) or (mg/mmol) in an early morning "spot" urine sample.( Inker,.et al 2012)
The 6 categories include:
* G1: GFR 90 ml/min per 1.73 m2 and above
* G2: GFR 60 to 89 ml/min per 1.73 m2
* G3a: GFR 45 to 59 ml/min per 1.73 m2
* G3b: GFR 30 to 44 ml/min per 1.73 m2
* G4: GFR 15 to 29 ml/min per 1.73 m2
* G5: GFR less than 15 ml/min per 1.73 m2 or treatment by dialysis The three levels of albuminuria include an albumin-creatinine ratio (ACR)
* A1: ACR less than 30 mg/gm (less than 3.4 mg/mmol)
* A2: ACR 30 to 299 mg/gm (3.4 to 34 mg/mmol)
* A3: ACR greater than 300 mg/gm (greater than 34 mg/mmol). (Inker.,et al2014). hematological parameters such as white blood cell (WBC) include total leukocyte and differential counts, platelet (PLT), and red blood cell (RBC). Parameters, Kidney function ,electrolytes such as Na,k,ca and liver function bleeding time, and pro-thrombin time, are usually affected in CKD . These are common in CKD due to erythropoietin deciency and other factors such as increased hemolysis, suppression of bone marrow erythropoiesis, hematuria, and gastro intestinal blood loss. (George.,et al2015).
All CKD patients, particularly those with an estimated GFR (eGFR) \< 60 mL/min/1.73 m2, should be screened for anemia on initial evaluation for CKD. Anemia is defined as Hb \< 13 g/dL in men and Hb \< 12 g/dL in women, according to WHO criteria. (Hira Shaikh.,et al 2023).
the primary cause of anemia in patients with CKD is insufficient production of erythropoietin by the diseased kidneys. Other factors include iron, folate \& B12 deficiency due to nutritional insufficiency or increased blood loss (Hira Shaikh.,et al 2023). acute and chronic inflammation with impaired iron utilization, sever hyperparathyroidism with consequent bone marrow fibrosis and shortened red cell survival in the uremic environment, bleeding due to dysfunctional platelets, and rarely blood loss from hemodialysis(Hira Shaikh.,et al 2023).
Criteria used to define iron deficiency are different among CKD compared to normal renal function. Among CKD patients, absolut iron deficiency is defined when the transferrin saturation (TSAT) is ≤20% and the serum ferritin concentration is ≤100 ng/mL among predialysis and peritoneal dialysis patients or ≤200 ng/mL among hemodialysis patients. Functional iron deficiency, also known as iron-restricted erythropoiesis, is characterized by TSAT ≤20% and elevated ferritin levels. (TSAT = plasma iron divided by the total iron-binding capacity × 100)( Cappellini .,et al 2017) .
untreated prolonged anemia leads to a number of physiologic disorders, including: cardiovascular complications like decreased tissue oxygenation, increased cardiac output, ventricular dilatation and ventricular hypertrophy and increased mortality and morbidity.( Dwijen Das ., et al 2015).
Iron supplementation is recommended for all CKD patients with anemia. There is general agreement according to guidelines that intravenous (i.v.) iron supplementation is the preferred method for CKD patients on dialysis (CKD stage 5D) and either i.v. or oral iron is recommended for patients with CKD(Tolkien.,et al 2015)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Children with chronic kidney disease in stage 1 and 2.
* Children with liver disease.
* Children known blood disorder rather than anemia.
* Children with malignancy.
* Children with recent bleeding tendancy.
1 Year
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Assiut University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zeinab Othman AbdelGaleel
principal investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kotb Abbass, professor
Role: STUDY_DIRECTOR
Assiut University
Asmaa Ahmed, lecture
Role: STUDY_DIRECTOR
Assiut University
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
References
Explore related publications, articles, or registry entries linked to this study.
Hashmi MF, Shaikh H, Rout P. Anemia of Chronic Kidney Disease. 2024 Jul 23. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from http://www.ncbi.nlm.nih.gov/books/NBK539871/
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
hematological profile in CKD
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.